Načítá se...
Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals
INTRODUCTION: The FDA issued a warning following 24 cases of HBV reactivation during DAA therapy for HCV, including individuals with inactive, occult and past HBV infection. Clinical presentations ranged from asymptomatic fluctuations in HBV DNA to fulminant hepatic failure, liver transplantation an...
Uloženo v:
| Vydáno v: | Expert Opin Drug Saf |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5589072/ https://ncbi.nlm.nih.gov/pubmed/28471314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2017.1325869 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|